AtriCure, Inc. is a medical device maker focused on surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain. Because the stock has climbed sharply, its overall analyst consensus now sits below the latest price: S&P Global data shows a mean target near $57.56, with estimates ranging from roughly $36 to $70. For this reason, the central target used here is not the full consensus but the average of the verified targets above the current price.
Six current, above-price targets were reviewed. BTIG (Marie Thibault), Needham (Mike Matson), and Piper Sandler (Matt O'Brien) each raised their targets to $70 following the company's better-than-expected third-quarter results, while Citizens JMP ($68), Canaccord ($67), and Stifel ($65) sit just below. Their mean is $68.33, rounded to $68. UBS ($50) and Freedom Capital ($57) hold lower targets, and Freedom Capital downgraded the stock to Hold in October, arguing it trades at a significant premium to peers.
With a last close near $60.41, reaching $68 would require an advance of about 12.6%, a modest move by historical standards but notable after the shares more than doubled from roughly $28 in late June 2026. The 52-week high stands near $61.71, so the stock is trading just below that level. A sustained move toward $68 would likely depend on continued momentum in the pain-management business, which grew 27% year over year in the first half of 2026, plus steady gains in open ablation and appendage management.
The company's fundamentals have improved markedly. Total revenue has grown about 14% over the past year, with a gross margin near 76%, and management raised profitability guidance alongside its latest report. Analysts cite a new Society of Thoracic Surgeons (STS) quality measure favoring pre-operative Afib treatment as an underappreciated catalyst for open ablation. Longer term, results from the BoX-NoAF trial for post-operative atrial fibrillation, expected in early 2027, could support label expansion and a larger addressable market.
Valuation is the central concern. The stock trades at a forward P/E (price-to-earnings ratio) above 200 times, leaving little margin for error if growth decelerates. Pulsed field ablation competition from larger rivals such as Edwards Lifesciences (EW) and Boston Scientific (BSX) has already prompted downgrades. Any shortfall in pain-management momentum, softer guidance, or disappointing BoX-NoAF data could compress the multiple and pressure the shares.
The stock is hovering just below its 52-week high near $61.71, which acts as the nearest resistance zone; a decisive break above that level would put the $65 and $68 analyst targets into view. On the downside, the $55–$57 area, where several lower analyst targets cluster, represents a potential support zone. The sharp run since mid-2026 leaves the shares extended, meaning pullbacks could be swift if sentiment turns.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms do not publish identical timeframes. Key items to watch include quarterly revenue and guidance updates, the trajectory of the pain-management and open ablation segments, analyst target revisions, the BoX-NoAF trial readout expected in early 2027, and any competitive or regulatory developments in the pulsed field ablation market.
For investors seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool helps traders discover opportunities, track positions, and spot shifting trends more efficiently than manual screening. Explore the signals to see how AI can support your own market monitoring.
The $68 target is a real but selective figure: it is the average of the six analyst targets above AtriCure's current price, not the broader consensus, which sits below the stock near $57.56. Achieving it would require a modest 12.6% gain, supported by double-digit revenue growth, a fast-growing pain franchise, and upcoming clinical catalysts. However, a forward P/E above 200 times, intensifying pulsed field ablation competition, and the risk of a disappointing BoX-NoAF outcome are material obstacles. The wide $36-to-$70 target range reflects genuine disagreement about whether the recent rally has already priced in the company's growth. Investors should focus next on guidance, competitive updates, and the 2027 trial readout rather than any single price level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ATRC has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRC jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To ATRC | 1D Price Change % | ||
|---|---|---|---|---|
| ATRC | 100% | +1.54% | ||
| CERS - ATRC | 42% Loosely correlated | +2.32% | ||
| SIBN - ATRC | 41% Loosely correlated | -2.90% | ||
| IRMD - ATRC | 38% Loosely correlated | +0.38% | ||
| ICUI - ATRC | 38% Loosely correlated | +1.11% | ||
| TMCI - ATRC | 37% Loosely correlated | -1.31% | ||
More | ||||
| Ticker / NAME | Correlation To ATRC | 1D Price Change % |
|---|---|---|
| ATRC | 100% | +1.54% |
| Pharmaceuticals: Other industry (49 stocks) | 50% Loosely correlated | +0.20% |
| Pharmaceuticals industry (151 stocks) | 11% Poorly correlated | +0.11% |